[1]
|
Wang, X., Luo, K., Xu, Q., Chi, L., Guo, Y., Jia, C., et al. (2024) Prognostic Marker CD27 and Its Micro-Environmental in Multiple Myeloma. BMC Cancer, 24, Article No. 352. https://doi.org/10.1186/s12885-024-11945-z
|
[2]
|
Sakae, Y., Takada, H., Ichinose, S., Nakajima, M., Sakai, A. and Ogawa, R. (2023) Treatment with YIGSR Peptide Ameliorates Mouse Tail Lymphedema by 67 kDa Laminin Receptor (67LR)-Dependent Cell-Cell Adhesion. Biochemistry and Biophysics Reports, 35, Article 101514. https://doi.org/10.1016/j.bbrep.2023.101514
|
[3]
|
Yang, Y., Li, J., Lei, W., Wang, H., Ni, Y., Liu, Y., et al. (2023) CXCL12-CXCR4/CXCR7 Axis in Cancer: From Mechanisms to Clinical Applications. International Journal of Biological Sciences, 19, 3341-3359. https://doi.org/10.7150/ijbs.82317
|
[4]
|
Quagliano, A., Gopalakrishnapillai, A. and Barwe, S.P. (2023) Tetraspanins Set the Stage for Bone Marrow Microenvironment-Induced Chemoprotection in Hematologic Malignancies. Blood Advances, 7, 4403-4413. https://doi.org/10.1182/bloodadvances.2023010476
|
[5]
|
Wang, J., Shen, N., Shen, X., Zhang, R., Jin, Y., Li, J., et al. (2023) Survival Trends and Prognostic Factors of Patients with Newly Diagnosed Multiple Myeloma Accompanied with Extramedullary Disease. Annals of Medicine, 55, Article 2281657. https://doi.org/10.1080/07853890.2023.2281657
|
[6]
|
Sammartano, V., Cerase, A., Venanzi, V., Mazzei, M.A., Vangone, B.E., Gentili, F., et al. (2022) Central Nervous System Myeloma and Unusual Extramedullary Localizations: Real Life Practical Guidance. Frontiers in Oncology, 12, Article 934240. https://doi.org/10.3389/fonc.2022.934240
|
[7]
|
Dingli, D., Ailawadhi, S., Bergsagel, P.L., Buadi, F.K., Dispenzieri, A., Fonseca, R., et al. (2017) Therapy for Relapsed Multiple Myeloma. Mayo Clinic Proceedings, 92, 578-598. https://doi.org/10.1016/j.mayocp.2017.01.003
|
[8]
|
Gagelmann, N., Eikema, D., Koster, L., Netelenbos, T., McDonald, A., Stoppa, A., et al. (2023) Impact of Newly Diagnosed Extramedullary Myeloma on Outcome after First Autograft Followed by Maintenance: A CMWP-EBMT Study. European Journal of Haematology, 111, 181-190. https://doi.org/10.1111/ejh.13981
|
[9]
|
Li, Y., Sun, Z. and Qu, X. (2022) Advances in the Treatment of Extramedullary Disease in Multiple Myeloma. Translational Oncology, 22, Article 101465. https://doi.org/10.1016/j.tranon.2022.101465
|
[10]
|
Tabchi, S., Nair, R., Kunacheewa, C., Patel, K.K., Lee, H.C., Thomas, S.K., et al. (2019) Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia. Clinical Lymphoma Myeloma and Leukemia, 19, 560-569. https://doi.org/10.1016/j.clml.2019.05.001
|
[11]
|
Lakshman, A., Singh, P.P., Rajkumar, S.V., Dispenzieri, A., Lacy, M.Q., Gertz, M.A., et al. (2017) Efficacy of VDT Pace-Like Regimens in Treatment of Relapsed/Refractory Multiple Myeloma. American Journal of Hematology, 93, 179-186. https://doi.org/10.1002/ajh.24954
|
[12]
|
Moreau, P., Masszi, T., Grzasko, N., Bahlis, N.J., Hansson, M., Pour, L., et al. (2016) Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. New England Journal of Medicine, 374, 1621-1634. https://doi.org/10.1056/nejmoa1516282
|
[13]
|
Minarik, J., Pika, T., Radocha, J., Jungova, A., Straub, J., Jelinek, T., et al. (2021) Survival Benefit of Ixazomib, Lenalidomide and Dexamethasone (IRD) over Lenalidomide and Dexamethasone (Rd) in Relapsed and Refractory Multiple Myeloma Patients in Routine Clinical Practice. BMC Cancer, 21, Article No. 73. https://doi.org/10.1186/s12885-020-07732-1
|
[14]
|
Stewart, A.K., Rajkumar, S.V., Dimopoulos, M.A., Masszi, T., Špička, I., Oriol, A., et al. (2015) Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. New England Journal of Medicine, 372, 142-152. https://doi.org/10.1056/nejmoa1411321
|
[15]
|
Zhou, X., Flüchter, P., Nickel, K., Meckel, K., Messerschmidt, J., Böckle, D., et al. (2020) Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease. Cancers, 12, Article 1035. https://doi.org/10.3390/cancers12041035
|
[16]
|
Muchtar, E., Gatt, M.E., Rouvio, O., Ganzel, C., Chubar, E., Suriu, C., et al. (2015) Efficacy and Safety of Salvage Therapy Using Carfilzomib for Relapsed or Refractory Multiple Myeloma Patients: A Multicentre Retrospective Observational Study. British Journal of Haematology, 172, 89-96. https://doi.org/10.1111/bjh.13799
|
[17]
|
Rosiñol, L., Cibeira, M.T., Bladé, J., et al. (2004) Extramedullary Multiple Myeloma Escapes the Effect of Thalidomide. Haematologica, 89, 832-836.
|
[18]
|
Bladé, J., Perales, M., Rosiñol, L., Tuset, M., Montoto, S., Esteve, J., et al. (2001) Thalidomide in Multiple Myeloma: Lack of Response of Soft-Tissue Plasmacytomas. British Journal of Haematology, 113, 422-424. https://doi.org/10.1046/j.1365-2141.2001.02765.x
|
[19]
|
Avigdor, A., Raanani, P., Levi, I., Hardan, I. and Ben-Bassat, I. (2001) Extramedullary Progression Despite a Good Response in the Bone Marrow in Patients Treated with Thalidomide for Multiple Myeloma. Leukemia & Lymphoma, 42, 683-687. https://doi.org/10.3109/10428190109099330
|
[20]
|
Anagnostopoulos, A., Hamilos, G., Zorzou, M.P., Grigoraki, V., Anagnostou, D. and Athanasios Dimopoulos, M. (2004) Discordant Response or Progression in Patients with Myeloma Treated with Thalidomide-Based Regimens. Leukemia & Lymphoma, 45, 113-116. https://doi.org/10.1080/1042819031000151860
|
[21]
|
Myers, B., Grimley, C., Crouch, D. and Dolan, G. (2001) Lack of Response to Thalidomide in Plasmacytomas. British Journal of Haematology, 115, 234-234. https://doi.org/10.1046/j.1365-2141.2001.0115_1cr-6.x
|
[22]
|
Calvo-Villas, J.M., Alegre, A., Calle, C., Hernández, M.T., García-Sánchez, R. and Ramírez, G. (2011) Lenalidomide Is Effective for Extramedullary Disease in Relapsed or Refractory Multiple Myeloma. European Journal of Haematology, 87, 281-284. https://doi.org/10.1111/j.1600-0609.2011.01644.x
|
[23]
|
Patriarca, F., Prosdocimo, S., Tomadini, V., et al. (2005) Efficacy of Bortezomib Therapy for Extramedullary Relapse of Myeloma after Autologous and Non-Myeloablative Allogeneic Transplantation. Haematologica, 90, 278-279.
|
[24]
|
Laura, R., Cibeira, M.T., Uriburu, C., Yantorno, S., Salamero, O., Bladé, J., et al. (2006) Bortezomib: An Effective Agent in Extramedullary Disease in Multiple Myeloma. European Journal of Haematology, 76, 405-408. https://doi.org/10.1111/j.0902-4441.2005.t01-1-ejh2462.x
|
[25]
|
Paubelle, E., Coppo, P., Garderet, L., Azizi, L., Bories, D., Gorin, N., et al. (2005) Complete Remission with Bortezomib on Plasmocytomas in an End-Stage Patient with Refractory Multiple Myeloma Who Failed All Other Therapies Including Hematopoietic Stem Cell Transplantation: Possible Enhancement of Graft-vs-Tumor Effect. Leukemia, 19, 1702-1704. https://doi.org/10.1038/sj.leu.2403855
|
[26]
|
Krauth, M., Bankier, A., Valent, P., Kalhs, P. and Drach, J. (2005) Sustained Remission Including Marked Regression of a Paravertebral Plasmacytoma in a Patient with Heavily Pretreated, Relapsed Multiple Myeloma after Treatment with Bortezomib. Leukemia Research, 29, 1473-1477. https://doi.org/10.1016/j.leukres.2005.05.003
|
[27]
|
Alegre, A., Aguado, B., Giraldo, P., Ríos, E., Cánovas, A., Ibáñez, Á., et al. (2011) Lenalidomide Is Effective as Salvage Therapy in Refractory or Relapsed Multiple Myeloma: Analysis of the Spanish Compassionate Use Registry in Advanced Patients. International Journal of Hematology, 93, 351-360. https://doi.org/10.1007/s12185-011-0785-z
|
[28]
|
Shah, N., Chari, A., Scott, E., Mezzi, K. and Usmani, S.Z. (2020) B-Cell Maturation Antigen (BCMA) in Multiple Myeloma: Rationale for Targeting and Current Therapeutic Approaches. Leukemia, 34, 985-1005. https://doi.org/10.1038/s41375-020-0734-z
|
[29]
|
Short, K.D., Rajkumar, S.V., Larson, D., Buadi, F., Hayman, S., Dispenzieri, A., et al. (2011) Incidence of Extramedullary Disease in Patients with Multiple Myeloma in the Era of Novel Therapy, and the Activity of Pomalidomide on Extramedullary Myeloma. Leukemia, 25, 906-908. https://doi.org/10.1038/leu.2011.29
|
[30]
|
Jiménez-Segura, R., Granell, M., Gironella, M., Abella, E., García-Guiñón, A., Oriol, A., et al. (2019) Pomalidomide-Dexamethasone for Treatment of Soft-Tissue Plasmacytomas in Patients with Relapsed/Refractory Multiple Myeloma. European Journal of Haematology, 102, 389-394. https://doi.org/10.1111/ejh.13217
|
[31]
|
Li, Y., Ji, J., Lu, H., Li, J. and Qu, X. (2022) Pomalidomide-Based Therapy for Extramedullary Multiple Myeloma. Hematology, 27, 88-94. https://doi.org/10.1080/16078454.2021.2019364
|
[32]
|
Li, J., Shen, K., Huang, W., Li, L., Chen, H., Chen, W., et al. (2014) Autologous Stem Cell Transplant Can Overcome Poor Prognosis in Patients with Multiple Myeloma with Extramedullary Plasmacytoma. Leukemia & Lymphoma, 55, 1687-1690. https://doi.org/10.3109/10428194.2013.853296
|
[33]
|
Lee, S., Kim, J., Jeon, Y., Yoon, J., Shin, S., Eom, K., et al. (2014) Impact of Extramedullary Plasmacytomas on Outcomes According to Treatment Approach in Newly Diagnosed Symptomatic Multiple Myeloma. Annals of Hematology, 94, 445-452. https://doi.org/10.1007/s00277-014-2216-8
|
[34]
|
Kumar, L., Gogi, R., Patel, A.K., Mookerjee, A., Sahoo, R.K., Malik, P.S., et al. (2017) Multiple Myeloma with Extramedullary Disease: Impact of Autologous Stem Cell Transplantation on Outcome. Bone Marrow Transplantation, 52, 1473-1475. https://doi.org/10.1038/bmt.2017.165
|
[35]
|
Gagelmann, N., Eikema, D.J., Iacobelli, S., et al. (2018) Impact of Extramedullary Disease in Patients with Newly Diag-Nosed Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: A Study from the Chronic Malignancies Working Party of the EBMT. Haematologica, 103, 890-897.
|
[36]
|
Gagelmann, N., Eikema, D., Koster, L., Caillot, D., Pioltelli, P., Lleonart, J.B., et al. (2019) Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 25, 2134-2142. https://doi.org/10.1016/j.bbmt.2019.07.004
|
[37]
|
Jelinek, T., Sevcikova, T., Zihala, D., Popkova, T., Kapustova, V., Broskevicova, L., et al. (2021) Limited Efficacy of Daratumumab in Multiple Myeloma with Extramedullary Disease. Leukemia, 36, 288-291. https://doi.org/10.1038/s41375-021-01343-w
|
[38]
|
Jullien, M., Trudel, S., Tessoulin, B., Mahé, B., Dubruille, V., Blin, N., et al. (2019) Single-Agent Daratumumab in Very Advanced Relapsed and Refractory Multiple Myeloma Patients: A Real-Life Single-Center Retrospective Study. Annals of Hematology, 98, 1435-1440. https://doi.org/10.1007/s00277-019-03655-5
|
[39]
|
Lonial, S., Weiss, B.M., Usmani, S.Z., Singhal, S., Chari, A., Bahlis, N.J., et al. (2016) Daratumumab Monotherapy in Patients with Treatment-Refractory Multiple Myeloma (SIRIUS): An Open-Label, Randomised, Phase 2 Trial. The Lancet, 387, 1551-1560. https://doi.org/10.1016/s0140-6736(15)01120-4
|
[40]
|
Pick, M., Vainstein, V., Goldschmidt, N., Lavie, D., Libster, D., Gural, A., et al. (2018) Daratumumab Resistance Is Frequent in Advanced-Stage Multiple Myeloma Patients Irrespective of CD38 Expression and Is Related to Dismal Prognosis. European Journal of Haematology, 100, 494-501. https://doi.org/10.1111/ejh.13046
|
[41]
|
Dimopoulos, M., Bringhen, S., Anttila, P., Capra, M., Cavo, M., Cole, C., et al. (2021) Isatuximab as Monotherapy and Combined with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 137, 1154-1165. https://doi.org/10.1182/blood.2020008209
|
[42]
|
Attal, M., Richardson, P.G., Rajkumar, S.V., San-Miguel, J., Beksac, M., Spicka, I., et al. (2019) Isatuximab Plus Pomalidomide and Low-Dose Dexamethasone versus Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma (ICARIA-MM): A Randomised, Multicentre, Open-Label, Phase 3 Study. The Lancet, 394, 2096-2107. https://doi.org/10.1016/s0140-6736(19)32556-5
|
[43]
|
Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., et al. (2015) Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine, 373, 621-631. https://doi.org/10.1056/nejmoa1505654
|
[44]
|
Cho, S., Xing, L., Anderson, K.C. and Tai, Y. (2021) Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma. Cancers, 13, Article 6136. https://doi.org/10.3390/cancers13236136
|
[45]
|
Dimopoulos, M.A., Lonial, S., White, D., Moreau, P., Weisel, K., San-Miguel, J., et al. (2020) Elotuzumab, Lenalidomide, and Dexamethasone in RRMM: Final Overall Survival Results from the Phase 3 Randomized ELOQUENT-2 Study. Blood Cancer Journal, 10, Article No. 91. https://doi.org/10.1038/s41408-020-00357-4
|
[46]
|
Dimopoulos, M.A., Dytfeld, D., Grosicki, S., Moreau, P., Takezako, N., Hori, M., et al. (2018) Elotuzumab Plus Pomalidomide and Dexamethasone for Multiple Myeloma. New England Journal of Medicine, 379, 1811-1822. https://doi.org/10.1056/nejmoa1805762
|
[47]
|
Kashima, E., Fujieda, A., Nato, Y., et al. (2020) Successful Treatment with a Combination of Elotuzumab, Lenalidomide and Dexamethasone of Extramedullary Disease in a Patient with Refractory Multiple Myeloma. Rinsho Ketsueki, 61, 223-227. https://doi.org/10.11406/rinketsu.61.223
|
[48]
|
Danhof, S., Rasche, L., Mottok, A., Steinmüller, T., Zhou, X., Schreder, M., et al. (2021) Elotuzumab for the Treatment of Extramedullary Myeloma: A Retrospective Analysis of Clinical Efficacy and SLAMF7 Expression Patterns. Annals of Hematology, 100, 1537-1546. https://doi.org/10.1007/s00277-021-04447-6
|
[49]
|
Chim, C.S., Kumar, S.K., Orlowski, R.Z., Cook, G., Richardson, P.G., Gertz, M.A., et al. (2017) Management of Relapsed and Refractory Multiple Myeloma: Novel Agents, Antibodies, Immunotherapies and Beyond. Leukemia, 32, 252-262. https://doi.org/10.1038/leu.2017.329
|
[50]
|
Ali, S.A., Shi, V., Maric, I., Wang, M., Stroncek, D.F., Rose, J.J., et al. (2016) T Cells Expressing an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Multiple Myeloma. Blood, 128, 1688-1700. https://doi.org/10.1182/blood-2016-04-711903
|
[51]
|
Xu, J., Chen, L., Yang, S., Sun, Y., Wu, W., Liu, Y., et al. (2019) Exploratory Trial of a Biepitopic CAR T-Targeting B Cell Maturation Antigen in Relapsed/Refractory Multiple Myeloma. Proceedings of the National Academy of Sciences, 116, 9543-9551. https://doi.org/10.1073/pnas.1819745116
|
[52]
|
Deng, H., Liu, M., Yuan, T., Zhang, H., Cui, R., Li, J., et al. (2021) Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients with and without Extramedullary Disease. Frontiers in Immunology, 12, Article 720571. https://doi.org/10.3389/fimmu.2021.720571
|